GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (STU:PQX1) » Definitions » Cyclically Adjusted Revenue per Share

Biotage AB (STU:PQX1) Cyclically Adjusted Revenue per Share : €1.60 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Biotage AB Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biotage AB's adjusted revenue per share for the three months ended in Mar. 2024 was €0.530. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.60 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biotage AB's average Cyclically Adjusted Revenue Growth Rate was 13.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 18.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biotage AB was 18.40% per year. The lowest was 12.60% per year. And the median was 16.05% per year.

As of today (2024-05-15), Biotage AB's current stock price is €14.49. Biotage AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €1.60. Biotage AB's Cyclically Adjusted PS Ratio of today is 9.06.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biotage AB was 23.25. The lowest was 4.95. And the median was 12.85.


Biotage AB Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biotage AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB Cyclically Adjusted Revenue per Share Chart

Biotage AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.94 1.08 1.20 1.43 1.65

Biotage AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.47 1.43 1.54 1.65 1.60

Competitive Comparison of Biotage AB's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Biotage AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotage AB's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biotage AB's Cyclically Adjusted PS Ratio falls into.



Biotage AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biotage AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.53/130.9575*130.9575
=0.530

Current CPI (Mar. 2024) = 130.9575.

Biotage AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.205 100.432 0.267
201409 0.199 100.161 0.260
201412 0.226 100.225 0.295
201503 0.241 99.950 0.316
201506 0.247 99.995 0.323
201509 0.246 100.228 0.321
201512 0.281 100.276 0.367
201603 0.264 100.751 0.343
201606 0.270 101.019 0.350
201609 0.270 101.138 0.350
201612 0.285 102.022 0.366
201703 0.300 102.022 0.385
201706 0.311 102.752 0.396
201709 0.288 103.279 0.365
201712 0.294 103.793 0.371
201803 0.316 103.962 0.398
201806 0.355 104.875 0.443
201809 0.344 105.679 0.426
201812 0.353 105.912 0.436
201903 0.363 105.886 0.449
201906 0.407 106.742 0.499
201909 0.405 107.214 0.495
201912 0.422 107.766 0.513
202003 0.391 106.563 0.481
202006 0.372 107.498 0.453
202009 0.387 107.635 0.471
202012 0.449 108.296 0.543
202103 0.424 108.360 0.512
202106 0.459 108.928 0.552
202109 0.459 110.338 0.545
202112 0.504 112.486 0.587
202203 0.554 114.825 0.632
202206 0.563 118.384 0.623
202209 0.561 122.296 0.601
202212 0.528 126.365 0.547
202303 0.486 127.042 0.501
202306 0.504 129.407 0.510
202309 0.474 130.224 0.477
202312 0.718 130.958 0.718
202403 0.530 130.958 0.530

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biotage AB  (STU:PQX1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biotage AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=14.49/1.6
=9.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biotage AB was 23.25. The lowest was 4.95. And the median was 12.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biotage AB Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biotage AB's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotage AB (STU:PQX1) Business Description

Industry
Traded in Other Exchanges
Address
Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB (STU:PQX1) Headlines

No Headlines